Teva spinout delays NASH IPO while Galera prices below range

A NASH-focused spinoff of Teva Pharmaceuticals delayed its IPO and Galera priced below its $14-$16 range as the public waters grow murkier.

Touting an FGF21 analog cleaved off Teva’s pipeline, 89bio would have gone from Series A to Wall Street in less than a year had they completed the IPO they announced last month. Now, they’re being held up over an “issue” with the SEC and the company’s auditors said it could put the company in jeopardy.